Outer biosciences fast-tracks AI skincare with living skin tech

Outer Biosciences’ proprietary Yuna platform revolutionizes skin biology research by preserving donated human skin tissue alive and resilient for up to four weeks—far surpassing the industry norm of just a few days to one week. This extended viability enables detailed, longitudinal studies of slow biological processes such as collagen breakdown, inflammation, and cellular aging, while maintaining the skin’s structural integrity and resident immune cells. By sourcing tissue from over 300 donors representing all six Fitzpatrick skin tones, ages, and sexes, the company addresses regulatory demands for human-relevant testing and reduces reliance on animal models, ensuring diverse and applicable insights.

The platform’s integration of advanced biotechnology with machine learning accelerates skincare and cosmetic ingredient discovery by generating massive, high-dimensional datasets—over 30,000 data points per compound-sample pairing and more than 10 terabytes of data from 10,000 treatments. Outer Biosciences leverages AI models trained on living skin tissue responses to predict compound efficacy, enabling the company to reduce discovery timelines dramatically from identifying two promising compounds in 18 months to one every six weeks. This data-driven approach, focused exclusively on skin, produces unique biological insights unattainable through broader, generalized biology efforts.

Michael Polansky, co-founder and CEO, highlights a critical bottleneck in the field: while AI models improve rapidly, biological experimentation lags behind, limiting progress. Outer Biosciences bridges this gap by generating exceptional, high-quality data from a single organ system, enabling AI to be trained and validated effectively. This strategic focus on efficient and novel data generation allows the company to operate transparently in the skincare and cosmetic ingredient space, setting a new standard for AI-driven biotechnology innovation.

Outer Biosciences deliberately sidesteps traditional drug development pathways to focus on generating efficient and uniquely rich datasets that accelerate skincare and cosmetic ingredient innovation. CEO Michael Polansky emphasizes creating “special, new data that couldn't be generated any other way,” enabling the company to bypass the slow, complex pharmaceutical process and rapidly impact the market. Leveraging its AI-driven platform and proprietary skin preservation technology, Outer Biosciences has amassed over 10 terabytes of data from more than 300 donors and 10,000 potential treatments, with each compound-sample pairing producing upwards of 30,000 data points, underscoring a data-centric approach distinct from conventional biotech firms.

By concentrating exclusively on the skin as a single organ, Outer Biosciences carves out a specialized niche that bridges cosmetics and pharmaceuticals, aligning with substantial consumer demand for healthier skin solutions. Polansky notes that the choice of skin was deliberate, describing it as “a really interesting Venn diagram of enormous consumer demand,” which allows the company to apply deep expertise and targeted innovation rather than pursuing broad biological applications. This strategic focus positions Outer Biosciences uniquely to meet market needs while maintaining agility outside the traditional drug development framework.

Lady Gaga’s appointment to Outer Biosciences’ board significantly amplifies the company’s public profile and strategic momentum, leveraging her global celebrity to spotlight the firm’s cutting-edge biotech innovations in skin longevity. Co-founded with her fiancé Michael Polansky, Outer Bio’s mission to accelerate skincare ingredient discovery through its AI-driven Yuna platform aligns with Gaga’s influence to bridge advanced science and mainstream appeal. This celebrity leadership not only enhances visibility but also strategically supports the company’s commercial focus on rapidly bringing novel skin-health compounds to market, bypassing traditional drug development timelines.

AI-driven online skin analysis tools are revolutionizing the skincare industry by transforming skin assessment from a one-time diagnostic event into an ongoing, personalized digital service. Companies like Perfect Corp. leverage extensive, medically validated datasets—over 70,000 medical-grade facial images—to analyze more than 16 skin concerns with 95% test-retest reliability and over 80% correlation to physician assessments. This shift enables seamless integration of AI skin analysis into e-commerce, clinical, and retail workflows, enhancing customer engagement and product discovery while emphasizing the importance of training models on diverse populations to ensure equitable and responsible outcomes across different ages, skin tones, and types.

Outer Biosciences exemplifies cutting-edge AI-biotech convergence by maintaining living human skin tissue alive for up to a month—far surpassing the industry norm of a few days—to accelerate skincare and cosmetic ingredient discovery. This extended preservation window allows their AI models to predict compound efficacy, test them directly on living tissue, and iteratively learn from results, boosting their discovery rate from two promising compounds in 18 months to one every six weeks. Such advances underscore how integrating living tissue models with machine learning can dramatically enhance research efficiency and innovation speed in dermatological science.

The broader biotechnology landscape is witnessing remarkable progress in sustaining living tissue models for extended periods, as evidenced by breakthroughs like keeping lab-grown brain organoids alive for over five years—an order of magnitude longer than previous standards. These advancements enable researchers to delve deeper into complex biological processes and chronic diseases such as schizophrenia and epilepsy, illustrating a wider trend where prolonged viability of living models opens new frontiers for studying human biology and accelerating therapeutic discovery beyond dermatology.